Clinical trial
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
NCT00425555 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00425555 |
|---|---|
| Title | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma |
| Official title | A Phase II Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Panobinostat |
| Enrollment | 139 |
| Start date | Jan 1, 2007 |
| Primary completion | Jun 1, 2013 |
| Completion | Jun 1, 2013 |
| First posted | Jan 23, 2007 |
| Last update posted | Aug 20, 2021 |
| Countries | Argentina, Australia, Belgium, Canada, Finland, France, Germany, Hungary, Italy, Spain, Switzerland, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: